Entrectinib

What is Entrectinib?

Entrectinib is a groundbreaking oral medication classified as a targeted cancer therapy. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). This advanced medication is specifically designed to combat certain types of cancers that harbor particular genetic alterations. Marketed under the brand name Rozlytrek, Entrectinib offers a more personalized approach to cancer treatment by directly targeting the molecular drivers of tumor growth, rather than broadly affecting rapidly dividing cells like traditional chemotherapy.

Unlike conventional chemotherapy, which often comes with systemic side effects due to its non-specific action, Entrectinib works by inhibiting specific proteins that are overactive or mutated in cancer cells. This specificity allows for a more focused attack on the cancer, potentially leading to better efficacy and a different spectrum of side effects. It represents a significant advancement in precision medicine, providing hope for patients with challenging cancer diagnoses.

How Does Entrectinib Work?

The mechanism of action for Entrectinib is highly precise. It functions by inhibiting the activity of several crucial protein kinases: Tropomyosin Receptor Kinase (TRK) A, B, and C, ROS1 (ROS proto-oncogene 1), and ALK (anaplastic lymphoma kinase). These kinases, when aberrantly activated due to gene fusions or rearrangements, act as oncogenic drivers, promoting uncontrolled cell growth and survival in various cancers.

Specifically, Entrectinib targets tumors that express NTRK gene fusions (NTRK1, NTRK2, or NTRK3), ROS1 gene fusions, or ALK gene rearrangements. By binding to and inhibiting the kinase activity of these fusion proteins, Entrectinib effectively blocks the downstream signaling pathways that fuel cancer cell proliferation, survival, and metastasis. This blockade can lead to tumor regression and inhibition of further growth. Its ability to penetrate the central nervous system (CNS) is particularly important, making it effective against brain metastases, which are often difficult to treat with other therapies.

Medical Uses of Entrectinib

Entrectinib is approved for specific indications based on the presence of the aforementioned genetic alterations. Its primary medical uses include:

• NTRK Gene Fusion-Positive Solid Tumors: Entrectinib is approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion, are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, and who have either progressed following treatment or have no satisfactory alternative therapy. This indication is tumor-agnostic, meaning it can be used across various cancer types as long as the specific genetic fusion is present.
• ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): It is also indicated for the treatment of adult patients with metastatic ROS1-positive NSCLC. ROS1 rearrangements are a distinct subtype of NSCLC that can be highly responsive to targeted therapies like Entrectinib.
• ALK-Positive Non-Small Cell Lung Cancer: While primarily used for NTRK and ROS1 fusions, Entrectinib also demonstrates activity against ALK rearrangements, though other ALK inhibitors are often used first-line for this indication.

Before initiating Entrectinib therapy, patients must undergo comprehensive genomic profiling to confirm the presence of these specific gene fusions or rearrangements, ensuring the treatment is appropriate and has the highest chance of success.

Entrectinib Dosage

The dosage of Entrectinib is carefully determined by a healthcare professional based on the patient's condition, weight, and specific cancer type. For adult patients, the recommended oral dose is typically 600 mg once daily. For pediatric patients (12 years and older), the dosage is based on body surface area, with a maximum dose of 600 mg once daily.

Entrectinib capsules should be swallowed whole with or without food, but it is important to take it consistently at approximately the same time each day. If a dose is missed, it should be taken as soon as possible unless it is less than 12 hours before the next scheduled dose, in which case the missed dose should be skipped. Patients should not take two doses to make up for a missed dose. Dosage adjustments may be necessary based on the patient's tolerance to the drug and the severity of any side effects, as well as in cases of renal or hepatic impairment. Close monitoring by an oncologist is essential throughout the treatment period.

Entrectinib Side Effects

Like all medications, Entrectinib can cause side effects, although not everyone experiences them. Common side effects often include:

• Fatigue and weakness
• Nausea, vomiting, diarrhea, or constipation
• Dizziness or lightheadedness
• Dysgeusia (altered sense of taste)
• Weight gain
• Edema (swelling), particularly in the face and extremities
• Anemia

More serious side effects, though less common, can occur and require immediate medical attention. These may include:

• Congestive heart failure
• Central nervous system (CNS) effects such as cognitive impairment, mood changes (e.g., depression, anxiety), and dizziness
• Hepatotoxicity (liver problems)
• QT prolongation (a heart rhythm disorder)
• Hyperuricemia (high uric acid levels)
• Fractures

Patients should report any new or worsening symptoms to their doctor promptly. Regular monitoring of cardiac function, liver enzymes, electrolytes, and uric acid levels is typically performed during treatment.

Entrectinib Drug Interactions

Entrectinib is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. Therefore, it has several important drug interactions that patients and healthcare providers need to be aware of:

• Strong CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can significantly increase Entrectinib exposure, potentially leading to increased side effects. Dose reduction of Entrectinib may be necessary.
• Strong CYP3A4 Inducers: Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Entrectinib exposure, potentially reducing its effectiveness. Co-administration with these agents should generally be avoided.
• P-glycoprotein (P-gp) Inhibitors/Inducers: Entrectinib is also a substrate of P-gp, so drugs that inhibit or induce P-gp could alter its absorption and distribution.
• QT-Prolonging Drugs: Due to Entrectinib's potential to prolong the QT interval, caution is advised when co-administering with other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antibiotics).

Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking to prevent potential drug interactions.

Entrectinib FAQ

Q: Is Entrectinib a chemotherapy drug?

A: No, Entrectinib is a targeted therapy, not traditional chemotherapy. It specifically targets cancer cells with certain genetic mutations, rather than broadly attacking rapidly dividing cells.

Q: How is Entrectinib administered?

A: Entrectinib is taken orally as capsules, typically once daily.

Q: Can Entrectinib treat all types of cancer?

A: No, Entrectinib is effective only for cancers that have specific NTRK gene fusions, ROS1 gene fusions, or ALK gene rearrangements. Genetic testing is required to determine eligibility.

Q: What is the brand name for Entrectinib?

A: The brand name for Entrectinib is Rozlytrek.

Q: What if I miss a dose of Entrectinib?

A: If you miss a dose, take it as soon as you remember, unless it is less than 12 hours before your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses to catch up.

Q: Can I drink grapefruit juice while taking Entrectinib?

A: No, grapefruit juice and grapefruit products should be avoided while taking Entrectinib, as they can increase the drug's levels in your body and potentially lead to more side effects.

Products containing Entrectinib are available through trusted online pharmacies. You can browse Entrectinib-based medications at ShipperVIP or Medicenter.

Summary of Entrectinib

Entrectinib stands as a pivotal targeted cancer therapy, offering a precise and effective treatment option for patients whose cancers are driven by specific genetic alterations, namely NTRK gene fusions, ROS1 gene fusions, or ALK rearrangements. Its mechanism as a tyrosine kinase inhibitor allows it to specifically block the oncogenic signaling pathways, leading to tumor regression and controlled disease progression. The ability of Entrectinib to cross the blood-brain barrier also provides a significant advantage in treating CNS metastases. However, like all potent medications, it comes with a profile of potential side effects and drug interactions that necessitate careful monitoring and management by healthcare professionals. The advent of Entrectinib underscores the growing success of precision medicine in oncology, offering a tailored approach that significantly improves outcomes for eligible patients. Always consult with your doctor for personalized medical advice regarding Entrectinib or any cancer treatment.